So Let's Look at the Difference - Class Action and Investigational
NEW YORK, Oct. 16, 2013 /PRNewswire/ -- Bernstein Liebhard LLP today announced that a class action has been commenced in the United States District Court for the Southern District of New York on behalf of all those who purchased securities of MiMedx Group, Inc. (MDXG) ("MiMedx" or the "Company") between October 26, 2011 and September 4, 2013, inclusive (the "Class Period").
The Rosen Law Firm, P.A. announces that it is investigating potential securities claims against Osiris Therapeutics, Inc. (OSIR) resulting from allegations that the Company may have issued materially false statements to investors about the development and progress of its medical products.
One is a lawsuit and one is a fishing expedition.....
This will be sub $5 after the third quarter results are reported. Management has to come clean with the FDA letter. Analysts will ask the tough questions. Management will come clean. With all the law groups breathing down their back, management cannot give their usual misleading responses as in previous conference calls.
I'm here and keeping amused with how hard the Shorts are trying to swamp this message board. Apparently, they actually think the longs will believe their gibberish.
The facts are; Osiris is a very professional company and they have not taken an adversarial position with the FDA. As a result of good communications with the FDA, Osiris can still sell Grafix for DFUs along with other wound care indications while they navigate through the full FDA drug process.
The good news is; Osiris is rolling out the new OvationOS product and we've discovered a new product called Grafix XC and we've also been told that Osiris has already turned the corner to profitability. These facts are probably a big worry for the Shorts and part of the basis for all of the hurried negativity.